Gefitinib in elderly and unfit patients affected by advanced non-small-cell lung cancer

被引：63
|
作者：
Gridelli, C [1 ]
Maione, P
Castaldo, V
Rossi, A
机构：
[1] SG Moscati Hosp Via Circumvallaz, Div Med Oncol, I-83100 Avellino, Italy
[2] SG Moscati Hosp Via Circumvallaz, Direz Sanitaria, I-83100 Avellino, Italy
来源：
BRITISH JOURNAL OF CANCER | 2003年 / 89卷 / 10期
关键词：
NSCLC; gefitinib; elderly; poor PS patients;
D O I：
10.1038/sj.bjc.6601387
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Elderly and poor performance status advanced non-small-cell lung cancer ( NSCLC) patients often tolerate chemotherapy poorly. Special approaches are needed for these patient populations. Gefitinib ( Iressa) was used in 59 elderly and/or unfit NSCLC pretreated patients participating in a compassionate use programme showing some activity and good tolerability.
引用
收藏
页码：1827 / 1829
页数：3
相关论文
共 50 条
  • [41] Defining the issues in the treatment of elderly patients with advanced non-small-cell lung cancer
    Gajra, Ajeet
    LUNG CANCER MANAGEMENT, 2015, 4 (01) : 17 - 30
  • [42] Chemotherapy and Survival Benefit in Elderly Patients With Advanced Non-Small-Cell Lung Cancer
    Davidoff, Amy J.
    Tang, Mei
    Seal, Brian
    Edelman, Martin J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (13) : 2191 - 2197
  • [43] CONTINUATION MAINTENANCE FOR ELDERLY PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC)
    Okamoto, Isamu
    ANNALS OF ONCOLOGY, 2014, 25
  • [44] Docetaxel Versus Vinorelbine in Elderly Patients With Advanced Non-Small-Cell Lung Cancer
    Karampeazis, Athanasios
    Georgoulias, Vassilis
    CLINICAL LUNG CANCER, 2012, 13 (05) : 397 - 397
  • [45] PREDICTIVE FACTORS ASSOCIATED WITH GEFITINIB RESPONSE IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC)
    Xu, F.
    Zhou, T.
    Duan, J.
    ANNALS OF ONCOLOGY, 2012, 23 : 47 - 47
  • [46] Predictive factors associated with gefitinib response in patients with advanced non-small-cell lung cancer (NSCLC)
    Chen, Lian
    Chen, Rui
    Zhu, Zhe
    Zhang, Yichen
    Wen, Zhengwei
    Li, Yun
    Li, Xiaoming
    Luo, Yuwen
    Ma, Liyu
    Lin, Shuguang
    Chen, Xin
    CHINESE JOURNAL OF CANCER RESEARCH, 2014, 26 (04) : 466 - 470
  • [47] Is erlotinib really active after failure of gefitinib in advanced non-small-cell lung cancer patients?
    Vasile, E.
    Tibaldi, C.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2009, 20 (04) : 790 - 791
  • [48] Retrospective analysis of a group of patients with advanced Non-Small-Cell lung cancer (NSCLC) treated with Gefitinib
    Bandera, M.
    Bascialla, L.
    Martinelli, B.
    Masera, G. L. Rodolfo
    Vallini, I.
    Zanlorenzi, L.
    Pinotti, G.
    ANNALS OF ONCOLOGY, 2005, 16 : 25 - 25
  • [49] Gefitinib as front-line treatment in Chinese patients with advanced non-small-cell lung cancer
    Lin, Wei-Chun
    Chiu, Chao-Hua
    Liou, Jia-Ling
    Chen, Yuh-Min
    Perng, Reury-Perng
    Tsai, Chun-Ming
    LUNG CANCER, 2006, 54 (02) : 193 - 199
  • [50] A review of the benefit risk profile of gefitinib in Asian patients with advanced non-small-cell lung cancer
    Park, K
    Goto, K
    CURRENT MEDICAL RESEARCH AND OPINION, 2006, 22 (03) : 561 - 573
12345